Introduction: Previous studies in Ren-2 transgenic hypertensive rats (TGR) after 5/6 renal ablation (5/6 NX) have shown that besides pharmacological blockade of the renin-angiotensin system (RAS) also increasing kidney tissue epoxyeicosatrienoic acids (EET) levels by blocking soluble epoxide hydrolase (sEH), an enzyme responsible for degradation of EETs, and endothelin type A (ET A ) receptor blockade retards chronic kidney disease (CKD) progression. This prompted us to evaluate if this progression will be alleviated by the addition of sEH inhibitor and ET A receptor antagonist to the standard complex blockade of RAS (angiotensin-converting enzyme inhibitor plus angiotensin II type 1 receptor blocker) in rats with established CKD. Methods: The treatment regimens were initiated 6 weeks after 5/6 NX in TGR, and the followup period was 60 weeks. Results: The addition of sEH inhibition to RAS blockade improved survival rate, further reduced albuminuria and renal glomerular and kidney tubulointerstitial injury, and attenuated the decline in creatinine clearance -all this as compared with 5/6 NX TGR treated with RAS blockade alone. Addition of ET A receptor antagonist to the combined RAS and sEH blockade not only offered no additional renoprotection but, surprisingly, also abolished the beneficial effects of adding sEH inhibitor to the RAS blockade. Conclusion: These data indicate that pharmacological strategies that combine the blockade of RAS and sEH could be a novel tool to combat the progression of CKD. Any attempts to further extend this therapeutic regimen should be made with extreme caution.
Introduction
Chronic kidney disease (CKD) has become a growing public health problem [1, 2] . The natural course of progression from CKD to end-stage renal disease (ESRD) is known to be independent of the initial cause. However, the mechanisms underlying this appear to be quite similar [3] [4] [5] . It is generally agreed that diabetes mellitus, hypertension, and increased intrarenal activity of the renin-angiotensin system (RAS) are the most important factors influencing the progression of CKD to ESRD [4] [5] [6] [7] [8] . Therefore, the current "gold renoprotection paradigm" in patients with CKD is the antihypertensive therapy based on the RAS blockade, which has been shown to slow the progression of CKD to ESRD and attenuate cardiovascular disease [5, 8, 9] . However, the effectiveness of RAS blockade is limited, especially in advanced CKD. Apparently, new therapeutic regimens targeting hypertension in CKD are needed; however, no new drug for the treatment of CKD has been registered since 2001. This is so even though experimental studies suggested potential targets for novel treatments with substantial pertinent efforts in clinical research [10] [11] [12] . In order to study pathophysiological mechanism(s) of CKD and possible novel therapeutic measures to slow the progression of CKD to ESRD, the 5/6 renal ablation model is used [4, [13] [14] [15] [16] .
In the search for new pharmacological strategies targeting systems other than the RAS, attention has been recently directed to the endothelin (ET) system and to epoxyeicosatrienoic acids (EETs), cytochrome P-450 (CYP)-dependent metabolites of arachidonic acid.
ET-1 plays an important role in the pathophysiology of hypertension and end-organ damage, owing to the stimulation of type A receptors for ET-1 (endothelin type A [ET A ]) [17] [18] [19] [20] [21] [22] . The ET system is also activated in 5/6 NX model, and pharmacological blockade of either ET A alone or combined with complex pharmacological RAS inhibition was reported to be renoprotective in 5/6 NX Ren-2 renin transgenic rats (TGRs) -a model of angiotensin II-dependent hypertension with marked endogenous RAS activation [18, 19, [22] [23] [24] .
EETs exhibit antihypertensive actions that are related both to their vasodilatory properties and to inhibition of the renal tubular sodium transport. Intrarenal EETs might operate as a compensatory system to counterbalance inappropriately increased RAS activity [25, 26] . In addition, increasing renal EETs availability by blocking soluble epoxide hydrolase (sEH), an enzyme that converts EETs to biologically inactive dihydroxyeicosatrienoic acids, either alone or combined with standard RAS blockade, was reported to provide renoprotection in 5/6 NX TGR [27, 28] .
Nevertheless, it has to be admitted that only a small minority of the mentioned experimental results could be translated into clinical practice. The common limitation is that treatment was initiated almost immediately after 5/6 NX [3, 4, 15, 16, 22, 29] . Moreover, it has not been established if addition of ET A receptor blockade to the standard RAS blockade alone, or to the combined inhibition of sEH and RAS, would result in additive renoprotective effects.
Therefore, in the present study, we hypothetized whether the renoprotective effectiveness of combined RAS, sEH, and ET A receptor blockade (as compared with those of RAS blockade alone) in 5/6 NX TGR would be efficient even in the animals with already established CKD, explicitly, in TGR that were left untreated until 6 weeks after 5/6 NX ("late treatment protocol") [28, 30] . This model combines two critically important detrimental features promoting progression of CKD to ESRD: hypertension and increased intrarenal RAS activity [19, 30, 31] .
Methods

Animals
Heterozygous TGRs were used and age-matched Hannover-Sprague Dawley (HanSD) rats served as transgene-negative normotensive controls [23] .
Pharmacological Therapeutic Regimens
We and others have demonstrated that the pharmacological blockade using combination of ACEi and AT 1 blocker at increased doses provides a better cardio-and renoprotection [30] [31] [32] . Thus, similarly as in our recent studies [28, 30] , for the RAS blockade, a combination of trandolapril (6 mg/L drinking water, Gopten; Abbot, Prague, Czech Republic) and of losartan (Lozap, 100 mg/L drinking water, Zentiva, Prague, Czech Republic) was used.
The pharmacological blockade of sEH was achieved using the sEH inhibitor, cis-4-(4-[3adamantan-1-yl-ureido] cyclohexyloxy) benzoic acid, which was prepared freshly and given in drinking water at 3 mg/L [27, 33] .
ET A receptor blockade was achieved with atrasentan (5 mg kg -1 day -1 in drinking water; Abbott, IL, USA). The dose of atrasentan was adjusted weekly to actual water intake; such dosage was previously found to effectively block ET A receptors [30, 33, 34] .
Evaluation of Indices of Kidney Injury and of Creatinine Clearance
At the end of the appropriate follow-up period, animals were killed, and the kidneys were used to assess renal glomerular damage and tubulointerstitial injury. The kidneys were fixed in 4% formaldehyde and embedded in paraffin. Sections were stained with hematoxylin-eosin and periodic acid Schiff reaction then examined and evaluated in a blind-test fashion. Fifty glomeruli in each kidney were examined for glomerulosclerosis index (GSI) on a semi-quantitative scale as described previously [28, 30] . Renal cortical tubulointerstitial injury was evaluated as defined by Nakano et al. [35] and as used in our studies [28, 30, 31] .
Urinary rat albumin was measured by a quantitative sandwich enzyme immunoassay technique, using the commercially available ELISA kit (ERA3201-1, AssayPro, St. Charles, MO, USA). Plasma creatinine was measured by FUJI DRI-CHEM analyzer using appropriate slides for creatinine CRE-P III (FUJIFILM Corp., Tokyo, Japan). Urine creatinine was determined using Liquick Cor-CREATININE kit (PZ CORMAY S.A., Poland), measured at 500 nm. Clearance of creatinine was calculated using standard formula and was normalized per body weight.
Detailed Experimental Design Series 1: The Effects of Treatments on Survival Rate, Albuminuria, and Clearance of Endogenous Creatinine
In the week labeled -6, at the age of 6 weeks, male HanSD rats and TGR from several litters were exposed to 5/6 NX under general anesthesia (tiletamine + zolazepam, Virbac SA, Carros Cedex, France, 8 mg/kg; and xylasine, Spofa, Czech Republic, 4 mg/kg intramuscularly) as described previously [28, 30, 31] . After 24 h recovery, the animals were randomly assigned to experimental groups and were left with no treatment. Six weeks later (in the week 0), an appropriate treatment regimen was initiated or rats were left without treatment. The following experimental groups were investigated: 1 Sham-operated HanSD rats + water (initial n = 10) 2 Sham-operated TGR + water (n = 11) 3 5/6 NX TGR + water (n = 24) 4 5/6 NX TGR + RAS blockade (n = 27) 5 5/6 NX TGR + RAS blockade + sEH blockade (n = 28) 6 5/6 NX TGR + RAS blockade + sEH blockade + ET A blockade (n = 31).
The follow-up period was until week +60. In the weeks labeled 0, 2, 6, 10, 14, 24, 40, and 50 and after appropriate habituation training, the animals were placed in individual metabolic cages, and their 24 h urine was collected for determination of daily albuminuria and urinary creatinine excretion.
Series 2: The Effects of Treatments on the Development of Renal Glomerular Damage and Renal Cortical Tubulointerstitial Injury
Animals were again exposed to the same procedure (i.e., 5/6 NX or sham operation) as in series 1. In the week 0 (6 weeks after 5/6 NX or sham operation), the following groups were studied: 1 Sham-operated HanSD rats + water (n = 6) 2 Sham-operated TGR + water (n = 7) 3 5/6 NX TGR + water (n = 12).
In the weeks labeled 2, 6, and 24, the following separate groups were investigated (n represents always the number of animals at the time point of examination): 1 Sham-operated HanSD rats + water (n = 6) 2 Sham-operated TGR + water (n = 7) 3 5/6 NX TGR + water (n = 9) 4 5/6 NX TGR + RAS blockade (n = 11) 5 5/6 NX TGR + RAS blockade + sEH blockade (n = 10) 6 5/6 NX TGR + RAS blockade + sEH blockade + ETA blockade (n = 11).
At the end of the appropriate follow-up period, animals were killed, and renal glomerular damage and kidney tubulointerstial injury were assessed. The aim was (a) to evaluate the course of renal damage in untreated and treated animals with established CKD throughout the critical periods of the experiment; (b) to investigate whether the addition of sEH inhibitor and ET A receptor antagonist to standard RAS blockade will exhibit some beneficial effects on renal damage in addition to standard RAS blockade alone.
Statistical Analyses
Graph-Pad Prism software (Graph Pad Software, San Diego, CA, USA) was used for analyses. All values are expressed as mean ± SEM. Statistical analysis was done by Student t test, Wilcoxon's signed-rank test for unpaired data, or one-way analysis of variance when appropriate, analysis of variance for repeated measurements, followed by Student-Newman-Keuls test performed for the analysis within groups, when appropriate. Comparison of survival curves was performed by log-rank (Mantel-Cox) test followed by Gehan-Breslow-Wilcoxon test. In order to obtain reliable data regarding the effects of treatment regimens on the survival rate, high initial n values were used (not so for sham-operated animals) to enable valid comparison of the long-term survival rate, and those initial n values were estimated by statistical power analyses method developed by Cohen [36] .
The values exceeding 95% probability limits (p < 0.05) were considered statistically significant.
Results
Series 1: The Effects of Treatments on Survival Rate, Albuminuria, and Clearance of Endogenous Creatinine
In both sham-operated TGR and HanSD group, one animal unexpectedly died during the experiment (for unknown reasons); however, the survival rate remained above 90% at the end of experiment. As shown in Figure 1 , untreated 5/6 NX TGR began to die at week +1 (i.e., 7 weeks after 5/6 NX) and by week +10 no animal survived. The treatment with complex RAS blockade significantly improved the survival rate; however, beginning from week +10, the survival rate considerably decreased throughout the study and all animals died by week +50. Combined RAS and sEH blockade were more effective than complex RAS blockade alone, but survival decreased sharply after week +46 and no animal survived by week +58. Remarkably, combined complex RAS blockade together with sEH and ET A receptor blockade was not more effective than complex RAS blockade alone: throughout the experiment, there was no significant difference in the survival rate between these 2 treatment regimens ( Fig. 1 ).
As shown in Figure 2A , sham-operated HanSD rats showed minimal albuminuria throughout the experiment (at the end: 2.9 ± 2.8 mg/24 h). Sham-operated TGR revealed significantly higher albuminuria than sham-operated HanSD rats (about 3-fold higher), which slightly but progressively increased throughout the experiment. At the end of study, it was about 4-fold higher than that observed in sham-operated HanSD rats. However, compared with animals after 5/6 NX, the albuminuria remained noticeably lower. Untreated 5/6 NX TGR before initiating of appropriate treatment regimen (on week 0, i.e., 6 weeks after 5/6 NX) had albuminuria up to 20-fold higher than in the sham-operated TGR, and on weeks +2 and +6, it revealed a dramatic increase reaching the maximum on week +6 (469 ± 48 mg/24 h, p < 0.05 vs. all other corresponding values). On weeks +2 and +6, all treatment regimens were seen to attenuate albuminuria in 5/6 NX TGR, but it remained significantly higher than in sham-operated TGR. Remarkably, when viewed throughout the experiment, the combined complex RAS and sEH blockade was more effective in reducing albuminuria than either complex RAS blockade alone or the triad of complex RAS, sEH, and ET A receptor blockade.
There were no significant differences in creatinine clearance between sham-operated TGR and HanSD rats throughout the study (Fig. 2B ). Untreated 5/6 NX TGR demonstrated a profound decline in creatinine clearance on weeks +2 and +6, which was also associated with the dramatic onset of mortality ( Fig. 1 ). All treatment regimens in 5/6 NX TGR attenuated these decreases; however, the creatinine clearance remained significantly lower than that observed in sham-operated TGR. Nevertheless, after week +10, creatinine clearance in 5/6 NX TGR treated either with complex RAS blockade alone or the triad of complex RAS blockade, sEH and ET A receptor blockade began to decline and was significantly lower that observed in 5/6 NX TGR treated with complex RAS plus sEH blockade.
As shown in Figure 3A , when albuminuria was normalized for glomerular filtration rate (the albuminuria-to-creatinine clearance ratio), it was minimal and stable in sham-operated HanSD rats throughout the study. On the other hand, in sham-operated TGR, it progressively increased and at the end of the study was about 6-fold higher than in the normotensive counterparts.
Using the same index, in untreated 5/6 NX TGR albuminuria on week +6 was 740-fold higher (Fig. 3B ) than observed in sham-operated TGR on the same week (Fig. 3A) . As shown, all treatment regimens in 5/6 NX TGR reduced the albuminuria and, again, starting from week +6, the complex RAS blockade plus sEH blockade was more effective than complex RAS blockade alone or the triad of combined complex RAS plus sEH inhibition and ET A receptor blockade. The 6-week treatment with the RAS blockade plus sEH blockade attenuated the albuminuria in 5/6 NX TGR more than 20-fold as compared with untreated 5/6 NX TGR (0.13 ± 0.01 vs. 2.97 ± 0.21, p < 0.05; Fig. 3B ). Nevertheless, albuminuria on week +6 in 5/6 NX TGR treated with the RAS blockade and sEH blockade still remained about 30-times higher than observed in sham-operated TGR (0.13 ± 0.01 vs. 0.004 ± 0.0005, p < 0.05; Fig. 3A, B ).
Series 2: The Effects of Treatments on the Development of Renal Glomerular Damage and Renal Cortical Tubulointerstitial Injury
As shown in Figure 4A , already in week 0 (i.e., 6 weeks after 5/6 NX), untreated 5/6 NX TGR showed an obvious GSI increase, then the index increased further and in week +6 reached the value above 3, indicating an enormously severe renal glomerular damage. Treatment with complex RAS blockade alone or combined complex RAS blockade and sEH inhibition plus ET A receptor blockade attenuated the increases in GSI in 5/6 NX TGR, but their effectiveness markedly decreased in the late phase (on week +24, i.e., 30 weeks after 5/6 NX). In contrast, the treatment with complex RAS and sEH blockade remained effective throughout the experiment. Figure 4B shows that kidney tubulointerstitial injury followed a change pattern analogous in part with that observed for GSI; however, the RAS blockade alone and the RAS plus sEH plus ET A triad treatment were virtually ineffective over the whole follow-up period. 
Discussion
The crucial finding of the present study is that chronic treatment with sEH inhibitor when added to the complex RAS blockade in animals with established CKD brought additional renoprotective effects and attenuated the progression of CKD in 5/6 NX TGR. However, addition of ET A receptor blockade to this treatment regimen did not show additional benefit but, surprisingly, eliminated the beneficial effects of the combined RAS and sEH blockade. The present findings deserve special attention for several reasons.
First, a limited number of studies (including our earlier and the present ones) have evaluated treatment strategies in the phase of established CKD in the 5/6 NX model [28, 30, 37, 38] . It was clearly shown that when treatment was initiated in the established phase of CKD then the renoprotective effectiveness of the RAS blockade was significantly worse than when treatment was initiated shortly after 5/6 NX induction [3, 4, 15, 16, 22, 24, 29] . These findings further support the notion that, in order to be relevant to the clinical situation, effectiveness of renoprotective strategies should be evaluated at a time when some renal damage is already present.
Our present results further support the evidence that renoprotection afforded by RAS blockade alone is not extended to the late stage of CKD. It was apparent that 5/6 NX TGR treated with complex RAS blockade showed decreasing survival rate and creatinine clearance, and increasing albuminuria, renal glomerular damage, and kidney tubulointerstitial injury. Of special interest is the progressing increase in albuminuria because it is known that this parameter is correlated with a variety of important clinical outcomes, such as development of ESRD, cardiovascular disease, and all-cause mortality [5, 39] . Our results show, that even if the complex RAS blockade attenuated the albuminuria, it remained, when normalized to glomerular filtration rate, noticeably higher than in sham-operated TGR.
Special attention is also due to the additional renoprotective effects of the combined RAS and sEH blockade in 5/6 NX TGR as compared with the complex RAS blockade alone: not only improved survival rate but also further attenuation of albuminuria was seen. However, even though attenuated, the albuminuria in 5/6 NX TGR treated with the complex RAS and sEH blockade still remained elevated: in the critical point of a profound decrease in survival rate (i.e., in week +40), it was 13 fold higher than in sham-operated TGR and 80 fold higher than in sham-operated HanSD rats. Nevertheless, it was still > 4 fold lower than in 5/6 NX TGR treated with the complex RAS blockade alone. In addition, it is important to acknowledge that by week +40 the survival rate in 5/6 NX TGR treated with the complex RAS and sEH blockade decreased to 73% and in 5/6 NX TGR treated with the complex RAS blockade alone to 38%. It is apparent that between weeks +24 and +40 the animals with the highest albuminuria and lowest creatinine clearance were dying, which causes underestimation of the impact on albuminuria (a paradox of dying-dependent alteration of the estimate of albuminuria).
Why was it that addition of ET A receptor blockade to the combined RAS and sEH blockade not only did not bring any additional benefits but even abolished the beneficial renoprotective actions of the combined RAS plus sEH inhibition?
As evident from our recent [28] and the present findings, even if the dual RAS and sEH blockade exhibited the best renoprotective actions observed so far [18, 19, 22, 24, 27, 30, 31] , there is still considerable space for the therapeutic improvement. As is obvious from the actual course of survival rate and proteinuria (particularly in the late phase of experiment), the treated animals fared distinctly worse than did the sham-operated ones. Therefore, our attention focused on the ET system which we previously showed to be markedly activated after renal mass reduction in TGR [19, 24] . This activation augmented as CKD progressed toward the advanced CKD stage [30] . It will be noticed here that intrarenal overproduction of ET-1 and ET A receptor activation follows the same pathways that lead to the renal fibrosis and glomerulosclerosis induced by angiotensin II [11, 12, 21] . Moreover, important stimulatory interactions, at various levels, were found between the RAS and ET systems [12, 22, 40, 41] . Furthermore, pharmacological blockade of ET A receptors either alone or added to the complex blockade of the RAS brought important renoprotective effects in 5/6 NX TGR, at least when the treatment was introduced immediately after the renal mass reduction, that is, before any substantial kidney injury developed ("early treatment protocol") [19, 22, 24] . In the light of these facts, a sound rationale has been provided for addition of ET A receptor blockade to the combined RAS and sEH blockade in an attempt to treat CKD progression, particularly in the advanced phase of the disease.
The failure of ET A receptor blockade to show renoprotective effects additional to those induced by the combined RAS and sEH blockade was unexpected. However, even more astonishing was our finding that such addition eliminated the beneficial effects of sEH blockade (when added to RAS blockade) and virtually returned the treatment effectiveness to the level observed with RAS blockade alone. We cannot provide a satisfactory explanation for this finding; however, we must recall here the results of our parallel study which showed no additional renoprotective actions of ET A receptor blockade when added to complex RAS blockade (a dual treatment regimen and not the triad applied now) in the advanced phase of CKD in 5/6 NX TGR [30] . Taking into consideration the results of both our studies, we propose that in the very advanced phase of CKD, at least in 5/6 NX TGR, apart from the RAS and ET systems and CYP-dependent metabolites of arachidonic acid other neurohormonal systems must be involved. Moreover, the divergence of the results of the same pharmacological regimen when applied as "early treatment" versus "late treatment protocol" further exposes the need for novel renoprotective treatment strategies to be evaluated in preclinical studies of advanced CKD. Apparently, such studies are more relevant to the clinical situations and could possibly be translated into clinical practice.
Nevertheless, it still remains mysterious why addition of ET A receptor blockade (application of a therapeutic triad) abolished the beneficial renoprotective actions of the treatment by combined complex RAS and sEH blockade in 5/6 NX TGR. In this connection, it is important to emphasize that there is a growing evidence that, at least in 5/6 NX rats, renoprotection is blood pressure (BP) dependent [31, 42] . Since each of the 3 drugs employed in this study given alone exhibits significant BP-lowering action via different mechanisms [20, 25, 26, 34] in theory the combined therapy could have additive BP-lowering effect. If so, combined complex RAS blockade plus sEH inhibition plus ET A receptor blockade could bring BP below the renal blood flow autoregulation range [43, 44] . This might per se impair renal function and thereby oppose the renoprotective effects of the treatment. However, data from our recent studies [28, 30] and preliminary experiments in which BP was monitored by radiotelemetry in 5/6 NX TGR starting 6 weeks after renal mass reduction for 3 weeks show that within 72 h after initiation of the complex RAS blockade BP decreased to levels that were not significantly different from the values measured in sham-operated HanSD rats. Admittedly, we have no data on the long-term effect of the treatment on BP. All the same, it seems that addition of either sEH inhibitor or ET A receptor antagonist or their combination would not bring any additional BP-lowering effect. Therefore, one can assume that exaggerated BP-lowering effect was not the reason for the elimination of the beneficial effects of the combined RAS and sEH blockade in 5/6 NX TGR.
It is important to recognize that our present study reveals some limitations; for example, the evaluation of indices of kidney injury employed in our present study differs from the methods that are used in the clinical nephrology. However, it is important to emphasize that the method employed in our experimental study was introduced by Nakano et al. [35] , which is currently accepted as a gold standard for experimental studies in nephrology and, moreover, all our previous studies employed this semi-quantitative scale. Therefore, in order to compare the results of our previous (Vaněčková et al. [19] ; Čertíková Chábová et al. [24] ), current (Sedláková et al. [30] ; Čertíková Chábová et al. [28] ), and ongoing studies, we preserved this scoring method for the evaluation of kidney injury.
Conclusion
This study further strengthens the evidence that addition of pharmacological inhibition of sEH to the complex RAS blockade brings additional renoprotective effects and retards the progression of CKD in 5/6 NX TGR, also when the treatment is started in the established phase of CKD. The present data also show that addition of ET A receptor blockade to this treatment regimen does not bring additional renoprotection, in contrast, it was found to abolish the evident beneficial effects of the combined complex RAS and sEH blockade. All this information derived from the present experiments should be considered in attempts to develop new pharmacological strategies aimed at slowing down the progression of CKD to ESRD. So far, targeting CYP-derived metabolites of arachidonic acid at the level of sEH combined with RAS blockade seems a very promising approach.
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